Increased Serum Bilirubin Levels Coincident With Heart Failure Decompensation Indicate the Need for Intravenous Inotropic Agents
Authors:
Open Access
- 1 January 2007
- journal article
- Published by International Heart Journal (Japanese Heart Journal) in International Heart Journal
- Vol. 48 (2) , 195-204
Abstract
We have reported that chronic heart failure (HF) patients with increased serum bilirubin coincident with acute decompensation have a poor prognosis, indicating severe congestion and low tissue perfusion. The aim of this study was to analyze the possibility of increased bilirubin coincident with acute decompensation as a parameter which indicates the need for intravenous inotropic agents. We stratified 131 decompensated chronic HF patients with a LVEF ≤ 40% and systolic blood pressure between 90 and 120 mmHg, based on total bilirubin levels on admission. In patients with high bilirubin (T-Bil ≥ 1.2 mg/dL), intravenous inotropics contributed to significantly more abundant diuresis, body weight reduction, and decreases in bilirubin and serum creatinine in the first 5 in-hospital days compared to those without (group A: inotropics +; n = 24 versus group B: -; n = 38: 1726 ± 418 versus 1458 ± 424 mL/day: P < 0.05, -3.1 ± 1.6 versus -2.1 ± 2.2 kg: P < 0.05, -0.74 ± 0.51 versus -0.04 ± 0.60 mg/dL: P < 0.01, -0.29 ± 0.89 versus -0.01 ± 0.24 mg/dL: P < 0.01), in spite of no significant difference in the doses of diuretics between the 2 groups. On the contrary, patients with low bilirubin (T-Bil < 1.2 mg/dL) recovered from decompensation equally irrespective of inotropic administration (group C: inotropics +; n = 15 versus group D: -; n = 54: 1557 ± 329 versus 1507 ± 406 mL/day, -2.9 ± 1.7 versus -2.8 ± 1.5 kg, -0.01 ± 0.25 versus -0.08 ± 0.23 mg/dL, 0.02 ± 0.24 versus 0.47 ± 0.19 mg/dL; NS, respectively). Inotropics were administered after all because of unimproved hemodynamics in 26% of group B patients, compared to 4% of group D patients (P < 0.01). Increased bilirubin coincident with HF decompensation can be a useful marker indicating the need for intravenous inotropic agent administration.Keywords
This publication has 12 references indexed in Scilit:
- ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the AdultJACC, 2005
- Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of CardiologyEuropean Heart Journal, 2005
- Predictors of Congestive Heart Failure Mortality in Elderly People From the General Population The CArdiovascular STudy in the ELderly (CASTEL)International Heart Journal, 2005
- Plasma B-type Natriuretic Peptide Levels and Risk Factors for Congestive Heart Failure in a Japanese General PopulationInternational Heart Journal, 2005
- Type of liver dysfunction in heart failure and its relation to the severity of tricuspid regurgitationThe American Journal of Cardiology, 2002
- The Effectiveness and Relative Effectiveness of Intravenous Inotropic Drugs Acting Through the Adrenergic Pathway in Patients with Heart Failure—A Meta-Regression AnalysisEuropean Journal of Heart Failure, 2002
- Team Management of Patients With Heart FailureCirculation, 2000
- The epidemiology of heart failure: The Framingham StudyJACC, 1993
- Liver function abnormalities in chronic heart failure. Influence of systemic hemodynamicsArchives of internal medicine (1960), 1987
- Pharmacokinetics/pharmacodynamics of furosemide in man: A reviewJournal of Pharmacokinetics and Biopharmaceutics, 1979